135 related articles for article (PubMed ID: 16686368)
1. A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line.
Xiao Y; Davidson R; Smith A; Pereira D; Zhao S; Soglia J; Gebhard D; de Morais S; Duignan DB
Mol Pharm; 2006; 3(1):45-54. PubMed ID: 16686368
[TBL] [Abstract][Full Text] [Related]
2. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
3. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.
An G; Gallegos J; Morris ME
Drug Metab Dispos; 2011 Mar; 39(3):426-32. PubMed ID: 21139040
[TBL] [Abstract][Full Text] [Related]
4. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
Römermann K; Helmer R; Löscher W
Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
Chearwae W; Shukla S; Limtrakul P; Ambudkar SV
Mol Cancer Ther; 2006 Aug; 5(8):1995-2006. PubMed ID: 16928820
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism.
Pollex EK; Anger G; Hutson J; Koren G; Piquette-Miller M
Drug Metab Dispos; 2010 May; 38(5):740-4. PubMed ID: 20159988
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A.
Ejendal KF; Hrycyna CA
Mol Pharmacol; 2005 Mar; 67(3):902-11. PubMed ID: 15598974
[TBL] [Abstract][Full Text] [Related]
8. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
[TBL] [Abstract][Full Text] [Related]
9. Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.
Ni Z; Bikadi Z; Shuster DL; Zhao C; Rosenberg MF; Mao Q
Biochemistry; 2011 Sep; 50(37):8057-66. PubMed ID: 21854076
[TBL] [Abstract][Full Text] [Related]
10. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
[TBL] [Abstract][Full Text] [Related]
11. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
[TBL] [Abstract][Full Text] [Related]
12. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
Bates SE; Medina-Pérez WY; Kohlhagen G; Antony S; Nadjem T; Robey RW; Pommier Y
J Pharmacol Exp Ther; 2004 Aug; 310(2):836-42. PubMed ID: 15075385
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis.
Wang L; Leggas M; Empey PE; McNamara PJ
Drug Metab Dispos; 2012 May; 40(5):1024-31. PubMed ID: 22355035
[TBL] [Abstract][Full Text] [Related]
14. Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.
Ni Z; Bikadi Z; Cai X; Rosenberg MF; Mao Q
Am J Physiol Cell Physiol; 2010 Nov; 299(5):C1100-9. PubMed ID: 20739628
[TBL] [Abstract][Full Text] [Related]
15. A template model for studying anticancer drug efflux transporter inhibitors in vitro.
Sostelly A; Payen L; Guitton J; Di Pietro A; Falson P; Honorat M; Valdameri G; Geze A; Boumendjel A; Freyer G; Tod M
Fundam Clin Pharmacol; 2013 Oct; 27(5):544-56. PubMed ID: 22882086
[TBL] [Abstract][Full Text] [Related]
16. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).
Robey RW; Honjo Y; van de Laar A; Miyake K; Regis JT; Litman T; Bates SE
Biochim Biophys Acta; 2001 Jun; 1512(2):171-82. PubMed ID: 11406094
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
18. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
[TBL] [Abstract][Full Text] [Related]
19. The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2).
An G; Morris ME
Biopharm Drug Dispos; 2011 Nov; 32(8):446-57. PubMed ID: 21910126
[TBL] [Abstract][Full Text] [Related]
20. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]